Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL34P22 (ribosomal protein L34 pseudogene 22) is a human pseudogene, classified as a processed pseudogene related to the ribosomal protein L34 (RPL34) gene family[2][6][9][11]. Unlike the functional RPL34 gene, which encodes a component of the large 60S ribosomal subunit involved in protein synthesis, RPL34P22 does not encode a functional protein and is not believed to have an active biological role[2][9][11]. Pseudogenes like RPL34P22 arise from duplication or retrotransposition events and usually lack the regulatory elements or coding potential necessary to produce a functional product; therefore, it is not considered a molecular target for therapeutics or diagnostics[9][11]. Alternative names and identifiers include RPL34_12_1141, ENSG00000244267 (Ensembl), and 100271498 (NCBI Gene)[2][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L34 pseudogene 22 (RPL34P22).